| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1042845S |
| P356 | DOI | 10.1371/JOURNAL.PONE.0142845 |
| P932 | PMC publication ID | 4646457 |
| P698 | PubMed publication ID | 26571496 |
| P5875 | ResearchGate publication ID | 284020806 |
| P2093 | author name string | Peter Beitsch | |
| Neil L Spector | |||
| Sarah Bacus | |||
| Jennifer Harris | |||
| Kimberly Blackwell | |||
| Deborah A Smith | |||
| Kevin M Koch | |||
| Leanne Cartee | |||
| Eli Avisar | |||
| Faith C Robertson | |||
| Kelli Glenn | |||
| Carie L Kimbrough | |||
| Mark Gittelman | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas | Q28256478 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer | Q33597447 | ||
| Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse | Q33658203 | ||
| High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials | Q34201582 | ||
| Resiliency and vulnerability in the HER2-HER3 tumorigenic driver | Q34551761 | ||
| Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response | Q34600838 | ||
| DNA and its associated processes as targets for cancer therapy | Q34625003 | ||
| A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer | Q34650878 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies | Q35597532 | ||
| Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity | Q35684026 | ||
| Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy | Q35842908 | ||
| The EGF receptor is required for efficient liver regeneration | Q36089334 | ||
| Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members | Q36643816 | ||
| Oncogene addiction: setting the stage for molecularly targeted cancer therapy | Q37031755 | ||
| An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models | Q37690880 | ||
| Targeted cancer therapies in the twenty-first century: lessons from imatinib | Q37710963 | ||
| The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. | Q40021112 | ||
| Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure | Q40200893 | ||
| Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels | Q40657210 | ||
| The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. | Q40685410 | ||
| EGFR/Ras/MAPK signaling mediates adult midgut epithelial homeostasis and regeneration in Drosophila | Q41871121 | ||
| Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | Q44907727 | ||
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies | Q45246419 | ||
| Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer | Q46610979 | ||
| Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy | Q46796554 | ||
| EGFR, Wingless and JAK/STAT signaling cooperatively maintain Drosophila intestinal stem cells. | Q52609447 | ||
| Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. | Q53644250 | ||
| Tyrosine kinases as targets for cancer therapy | Q80367757 | ||
| Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose | Q80631160 | ||
| Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors | Q80726137 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| P304 | page(s) | e0142845 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor | |
| P478 | volume | 10 |
Search more.